Validation of novel imaging methodologies for use as cancer clinical trial end-points - Wikidata - awgldk - TriplyDB

Validation of novel imaging methodologies for use as cancer clinical trial end-points

Validation of novel imaging methodologies for use as cancer clinical trial end-points

http://www.wikidata.org/entity/Q33394106

about

A novel knowledge representation framework for the statistical validation of quantitative imaging biomarkers Can we negotiate with a tumor?Imaging biomarker roadmap for cancer studies The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data.Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities.Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study Current and future trends in imaging informatics for oncology RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline.Methods and challenges in quantitative imaging biomarker development Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy.Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI.White paper on imaging biomarkers Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy.Promise and pitfalls of quantitative imaging in oncology clinical trials.Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer.Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review.99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer.The Quantitative Imaging Network: NCI's Historical Perspective and Planned Goals.Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer.PET/CT in therapy evaluation of patients with lung cancer.Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab.RECIST - learning from the past to build the future.RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib-Treated Patients With Gastrointestinal Stromal Tumors.Intra-arterial therapies for liver cancer: assessing tumor response.Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design.Semi-automated volumetric quantification of tumor necrosis in soft tissue sarcoma using contrast-enhanced MRI.Ideal number of target lesions per organ to measure in metastatic colorectal cancer 18-Fluorodeoxyglucose positron emission tomography as a tool for response prediction in solid tumours.More randomization in phase II trials: necessary but not sufficient.Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.[Imaging in oncology: terms and definitions].FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma.The clinical evaluation of novel imaging methods for cancer management.Comparison of semi-automated and manual methods to measure the volume of liver tumours on MDCT images.Volumetric evaluation of hepatic tumors: multi-vendor, multi-reader liver phantom study.Biochemical and imaging biomarkers: the search for the Holy Grail.

P2860

Q26825076-8168762E-AA0A-4F78-A6CD-B765B084F7E1 Q28541524-E1047A28-F925-48C8-A565-9CE424262861 Q30242020-7AF9B796-C1BF-40C3-AA3A-CB378D8985D4 Q30882874-A05CC44E-4DD4-4C08-818B-94DE0F4CF2C9 Q33475230-1BA34007-F9FF-4DD1-907A-7202E1A381C8 Q33620499-0863D7EC-0741-4EA3-A4CC-26F9D4AD24B7 Q33655366-7A8CDB0C-4D11-4057-AE19-B6F29C401BA5 Q33728662-462E1E55-BC7F-4D22-B0E5-EB3EA0FF1814 Q33857343-B7766243-6224-456F-96EE-9B4C0053820D Q34648114-B4D8D8EE-AEF6-48A7-B7F2-D831DC226BAB Q34681148-71457F91-03A8-44E2-9548-173F9AA0B57F Q35148109-9A4D3E07-C47E-4F8B-B4CD-FCD6E1AE137A Q35600833-CB0104A7-F8C1-4CCE-A212-C3855FFB46A8 Q35675618-F05348DD-4A12-4CEF-AEF2-202D353936E1 Q35739540-5190B87C-998E-40BB-B8D3-B574D9F552A5 Q36303765-E748CCEC-CB3C-49ED-B278-9A6ACA0649CC Q36897213-DF377C1F-406D-419B-AA11-B0B6AB41E37D Q37046433-6BD0AEBC-AEFE-47A0-9E38-BBB498998FCC Q37061800-02ADD482-93E6-4FA3-8793-FFEBE3D2FBB1 Q37413611-FFC51327-5E3B-48D4-B60B-902082E9E66F Q37721565-6CD69BCA-7D0C-48D5-8B75-AACD2C1AEAF2 Q38026294-888626EC-9482-4DB1-8D8B-670427FB8D2F Q38202189-5C858708-60DA-444B-B0A5-18532BBE38BE Q38226264-A30FDC1F-1498-4911-81B5-DC347483BE07 Q38780372-90F20265-E113-41F8-9D66-5FBE7E8C560E Q38847450-91D18804-7FCB-49C6-8344-B5697B2E7D5A Q38852974-B1C10701-09E1-404F-AC6D-CF3CEC8C28FC Q39041266-A0FD84D5-B228-43B9-8638-F810481F6309 Q39272347-D6AD3DDA-9F64-423F-B89B-6FECF595034C Q41810446-ED35FEE6-B0E0-4EE2-A279-3293EFC9CC6A Q41960901-A4D43644-FFF8-4E22-B46D-48AF021D1421 Q42786728-E58E1F04-5483-43DE-9DEC-FF9843C99FCE Q42828526-D5B3996B-6E90-48E2-8125-36ECAAFE9EC5 Q43248494-4FD47F77-BC7C-4244-B163-3D109F64360C Q44472578-528EDA7E-2D64-45DA-A952-D8B4F21EDC7C Q46165601-904CA932-C168-4C71-B9D9-005E853091A5 Q50896909-16DD7E75-5F0F-411D-9BCE-A2C8F86C8099 Q53077502-837B04FC-287A-408D-805A-862FA951E7CD Q53080830-C3B437EF-A0A2-4840-BE8B-E99D8E2C530B Q53286696-A3305371-C1AB-4AE0-BA15-923B565FB73A

P2860

Validation of novel imaging methodologies for use as cancer clinical trial end-points

http://www.wikidata.org/entity/Q33394106

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Validation of novel imaging methodologies for use as cancer clinical trial end-points

@ast

Validation of novel imaging methodologies for use as cancer clinical trial end-points

@en

type

label

Validation of novel imaging methodologies for use as cancer clinical trial end-points

@ast

Validation of novel imaging methodologies for use as cancer clinical trial end-points

@en

prefLabel

Validation of novel imaging methodologies for use as cancer clinical trial end-points

@ast

Validation of novel imaging methodologies for use as cancer clinical trial end-points

@en

P1433

Q33394106-9936B0E0-069F-437F-AEDC-4598A3C24168

P1476

Q33394106-631CC92E-D81E-444B-8F94-83CE5967AB88

P2093

Q33394106-64710082-EE33-45F2-998A-6BBA13D6A258

Q33394106-A889062C-2419-44E5-8BC6-3470DBB5C1F2

Q33394106-BBD12332-FB44-40CB-BD3F-C68AE4DD96C4

Q33394106-D714872A-21E2-4DED-AC78-BCCC15E4E762

Q33394106-E1C852D0-F976-41BA-BE63-9ADE0CF6310E

Q33394106-E575AF10-9428-4F42-9C35-DCE81638A700

P2860

Q33394106-054B363E-BEC6-4A66-A9E2-9DC64CEDEA96

Q33394106-0D25F65B-6FE0-4F0C-A08C-86CC8CB62FB8

Q33394106-21001663-81B0-4F43-A636-12C43837C135

Q33394106-2C5DB554-9D44-4A17-9CA3-901E7B954296

Q33394106-2DD724AB-7388-41D1-8997-A5179363299F

Q33394106-316647E7-78AF-4B80-9127-0727784B875B

Q33394106-34E44CE9-B3B7-47B9-B01A-50CC319D0A32

Q33394106-3CCA0FCB-EE0F-4690-B6B1-A622E40A42E9

Q33394106-44CE5E09-F4B3-404A-9315-7ABA24BAD1CB

Q33394106-462104D5-38FD-41DC-BDC8-FEE15C3B4298

P304

Q33394106-01106EA7-093C-4654-948E-7397D53EFA30

P31

Q33394106-C51C97BE-4AE2-441A-A2B9-34D150088F47

P356

Q33394106-C9670E0F-ECD9-4FEC-B8EF-C23D0201E4D4

P433

Q33394106-C45A2F99-74D1-4AD0-8502-A67B30A532EB

P478

Q33394106-828D2BD5-4DFA-49F2-AC00-D9EC64DF19C3

P50

Q33394106-48AB5715-3B52-4E52-9EF5-ACAEA4AB4C19

P577

Q33394106-A02B0B76-8874-4408-B18A-A09EA4D4AA72

P5875

Q33394106-EA6D288A-C939-4DAE-AB6D-613EFA250469

P698

Q33394106-A5CE92C3-6D15-4FEB-ACDE-9A254D455739

P932

Q33394106-F5A749BA-88F6-4B39-ACFB-ACCAEE1FC1D9

P356

J.EJCA.2008.10.030

P1433

European Journal of Cancer

P1476

Validation of novel imaging methodologies for use as cancer clinical trial end-points

@en

P2093

C Gatsonis

http://www.w3.org/2001/XMLSchema#string

J E Dancey

http://www.w3.org/2001/XMLSchema#string

L E Dodd

http://www.w3.org/2001/XMLSchema#string

L K Shankar

http://www.w3.org/2001/XMLSchema#string

L Rubinstein

http://www.w3.org/2001/XMLSchema#string

L Schwartz

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Use of PET for monitoring cancer therapy and for predicting outcome.

P304

290-299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJCA.2008.10.030

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

Daniel J. Sargent

P577

2008-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23672598

http://www.w3.org/2001/XMLSchema#string

P698

19091547

http://www.w3.org/2001/XMLSchema#string

P932

2802223

http://www.w3.org/2001/XMLSchema#string